R520A——mRNA COVID - 19 vaccine
- The self-developed freeze-drying technology was applied to achieve the stability of the preparation at 4℃ and 25℃
- Data showed that the lyophilization process did not affect the key physicochemical parameters, biological activity and immunogenicity of the vaccine
- It is expected to become the world's first lyophilized dosage form mRNA vaccine
In August 2021, together with our business partners including Shenzhen Rhegen, we established a joint venture, namely Wuhan Recogen for the R&D and commercialization of mRNA vaccines. As the first step of this collaboration, we are developing R520A, a clinical research stage mRNA COVID-19 vaccine candidate, which specifically targets Omicron variant. R520A adopts a selfdeveloped lyophilization technology. Through this approach, we can effectively sustain the physiochemical properties and bioactivity of mRNA-LNP and achieve long-term storage at 2°C – 8°C. We have been approved by the State Food and Drug Administration of the Philippines for clinical trials.